Skip to content
Disclosery

Ghost Tree Capital, LLC

Follow

13F filer, CIK 1595851, NEW YORK, NY

Ghost Tree Capital, LLC reported $361,294,423 across 72 holdings for the quarter ended 2024-03-31, in a 13F-HR filed 2024-05-15. Its ten largest share positions make up 41.8% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-24-000902

Period
2024-03-31
Reported value
$361M
Holdings
72
Top 10 weight
41.8%
New
33
Sold out
13

Largest buys vs the previous quarter

SecurityShares changeApprox. value
MLTXadded+220,000$11.1M
TGTXadded+575,000$8.75M
APLSnew+130,000$7.64M
ROIVadded+700,000$7.38M
BLUEPRINT MEDICINES CORPnew+72,761$6.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AMBRX BIOPHARMA INCexited-475,000-$6.76M
KRYSreduced-36,000-$6.41M
ARGXexited-15,000-$5.71M
TSHAreduced-1,150,000-$3.3M
GPCRreduced-75,000-$3.21M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2024

Share positions as resolved from 13F-HR 0001420506-24-000902, largest first. % of portfolio is the value over $311,055,173, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 235,000 shares; 2023Q1: 225,000 shares; 2023Q2: 110,000 shares; 2023Q3: 110,000 shares; 2023Q4: 165,000 shares; 2024Q1: 210,000 shares 210,000$16.8M5.39%+45,000Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 55,000 shares; 2023Q1: 60,000 shares; 2023Q2: 85,000 shares; 2023Q3: 40,000 shares; 2023Q4: 100,000 shares; 2024Q1: 125,000 shares 125,000$16.2M5.2%+25,000Timeline
BHVNBIOHAVEN LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 275,000 shares; 2024Q1: 285,000 shares 285,000$15.6M5.01%+10,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 195,000 shares; 2023Q2: 330,000 shares; 2023Q3: 330,000 shares; 2023Q4: 80,000 shares; 2024Q1: 300,000 shares 300,000$15.1M4.84%+220,000Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 64,000 shares; 2023Q3: 64,000 shares; 2023Q4: 600,000 shares; 2024Q1: 1,300,000 shares 1,300,000$13.7M4.41%+700,000Timeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,100,000 shares; 2023Q2: 825,000 shares; 2023Q3: 1,000,000 shares; 2023Q4: 250,000 shares; 2024Q1: 825,000 shares 825,000$12.5M4.03%+575,000Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 165,000 shares; 2023Q1: 175,000 shares; 2023Q2: 240,000 shares; 2023Q3: 275,000 shares; 2023Q4: 300,000 shares; 2024Q1: 625,000 shares 625,000$10.9M3.52%+325,000Timeline
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 80,000 shares; 2023Q1: 80,000 shares; 2023Q2: 150,000 shares; 2023Q3: 400,000 shares; 2023Q4: 300,000 shares; 2024Q1: 300,000 shares 300,000$10.9M3.51%0Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 101,443 shares; 2023Q4: 65,000 shares; 2024Q1: 200,000 shares 200,000$9.36M3.01%+135,000Timeline
ALNYALNYLAM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 27,500 shares; 2024Q1: 60,000 shares 60,000$8.97M2.88%+32,500Timeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 112,385 shares; 2024Q1: 200,000 shares 200,000$8.56M2.75%+87,615Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 750,000 shares; 2024Q1: 1,600,000 shares 1,600,000$7.97M2.56%+850,000Timeline
APLSAPELLIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 164,620 shares; 2023Q2: 180,000 shares; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 130,000 shares 130,000$7.64M2.46%newTimeline
PERSPECTIVE THERAPEUTICS INCPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 1,600,000 shares; 2024Q1: 6,000,000 shares 6,000,000$7.14M2.3%+4,400,000
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 20,000 shares; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 72,761 shares 72,761$6.9M2.22%new
AEROVATE THERAPEUTICS INCAEROVATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 135,000 shares; 2023Q1: 200,000 shares; 2023Q2: 201,197 shares; 2023Q3: 201,197 shares; 2023Q4: 210,000 shares; 2024Q1: 225,000 shares 225,000$6.65M2.14%+15,000
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 160,000 shares; 2023Q1: 225,000 shares; 2023Q2: 280,000 shares; 2023Q3: 140,000 shares; 2023Q4: 70,000 shares; 2024Q1: 95,000 shares 95,000$6.49M2.09%+25,000Timeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 150,000 shares; 2024Q1: 375,000 shares 375,000$6.4M2.06%+225,000Timeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 600,000 shares; 2023Q2: 650,000 shares; 2023Q3: 225,000 shares; 2023Q4: not reported; 2024Q1: 73,002 shares 73,002$5.99M1.92%newTimeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 125,000 shares 125,000$5.42M1.74%newTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 25,000 shares; 2023Q2: 42,000 shares; 2023Q3: 75,000 shares; 2023Q4: 125,000 shares; 2024Q1: 175,000 shares 175,000$5.41M1.74%+50,000Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 10,865 shares; 2023Q3: not reported; 2023Q4: 400,000 shares; 2024Q1: 650,000 shares 650,000$5.31M1.71%+250,000Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 154,250 shares; 2023Q3: 395,000 shares; 2023Q4: 385,241 shares; 2024Q1: 485,000 shares 485,000$5.15M1.66%+99,759Timeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 80,000 shares; 2023Q4: 50,000 shares; 2024Q1: 225,000 shares 225,000$4.16M1.34%+175,000Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 150,000 shares 150,000$4.07M1.31%newTimeline
TNYATENAYA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 775,000 shares 775,000$4.05M1.3%newTimeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 130,000 shares; 2023Q4: not reported; 2024Q1: 125,000 shares 125,000$4.04M1.3%newTimeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 100,000 shares 100,000$3.79M1.22%newTimeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 150,000 shares; 2023Q1: 325,000 shares; 2023Q2: 350,000 shares; 2023Q3: 200,000 shares; 2023Q4: not reported; 2024Q1: 150,000 shares 150,000$3.57M1.15%newTimeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 200,000 shares 200,000$3.39M1.09%newTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 75,000 shares 75,000$3.29M1.06%newTimeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 55,000 shares; 2023Q4: 150,000 shares; 2024Q1: 75,000 shares 75,000$3.21M1.03%-75,000Timeline
HELIX ACQUISITION CORP IIHELIX ACQUISITION CORP IIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 300,000 shares 300,000$3.12M1%new
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 800,000 shares; 2023Q1: 550,000 shares; 2023Q2: 575,000 shares; 2023Q3: 650,000 shares; 2023Q4: 195,000 shares; 2024Q1: 450,000 shares 450,000$3.02M0.97%+255,000Timeline
AQSTAQUESTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 702,941 shares 702,941$2.99M0.96%newTimeline
DECIPHERA PHARMACEUTICALS INDECIPHERA PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 325,000 shares; 2023Q4: 225,000 shares; 2024Q1: 176,513 shares 176,513$2.78M0.89%-48,487
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 1,325,000 shares; 2023Q4: 2,100,000 shares; 2024Q1: 950,000 shares 950,000$2.73M0.88%-1,150,000Timeline
GERNGERON CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 450,000 shares; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 800,000 shares 800,000$2.64M0.85%newTimeline
MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 135,000 shares; 2024Q1: 285,000 shares 285,000$2.58M0.83%+150,000
ALTALTIMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 250,000 shares 250,000$2.54M0.82%newTimeline
RGNXREGENXBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 120,000 shares 120,000$2.53M0.81%newTimeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 20,000 shares; 2023Q3: 80,000 shares; 2023Q4: 50,000 shares; 2024Q1: 14,000 shares 14,000$2.49M0.8%-36,000Timeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 100,000 shares; 2023Q4: 130,036 shares; 2024Q1: 200,000 shares 200,000$2.37M0.76%+69,964Timeline
NTRANATERA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 35,000 shares; 2024Q1: 25,000 shares 25,000$2.29M0.74%-10,000Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 200,000 shares 200,000$2.26M0.73%newTimeline
CRBPCORBUS PHARMACEUTICALS HLDGSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 56,941 shares 56,941$2.23M0.72%newTimeline
REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 250,000 shares; 2023Q2: 525,000 shares; 2023Q3: 350,000 shares; 2023Q4: 375,000 shares; 2024Q1: 450,000 shares 450,000$2.21M0.71%+75,000
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 225,000 shares; 2023Q2: 225,000 shares; 2023Q3: 400,000 shares; 2023Q4: 125,000 shares; 2024Q1: 75,000 shares 75,000$2.17M0.7%-50,000Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 325,000 shares; 2023Q4: 165,000 shares; 2024Q1: 90,000 shares 90,000$1.86M0.6%-75,000Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 20,000 shares; 2023Q1: 30,000 shares; 2023Q2: 55,000 shares; 2023Q3: 57,500 shares; 2023Q4: 15,000 shares; 2024Q1: 6,500 shares 6,500$1.74M0.56%-8,500Timeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: 59,250 shares; 2024Q1: 40,000 shares 40,000$1.65M0.53%-19,250Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 450,000 shares; 2023Q1: 450,000 shares; 2023Q2: 300,173 shares; 2023Q3: 300,000 shares; 2023Q4: 335,000 shares; 2024Q1: 115,000 shares 115,000$1.62M0.52%-220,000
LRMRLARIMAR THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 210,603 shares 210,603$1.6M0.51%newTimeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 90,000 shares; 2023Q4: 10,000 shares; 2024Q1: 20,000 shares 20,000$1.4M0.45%+10,000Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 600,000 shares 600,000$1.31M0.42%newTimeline
ELEVATION ONCOLOGY INC COMELEVATION ONCOLOGY INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 250,000 shares 250,000$1.28M0.41%new
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 25,000 shares 25,000$1.27M0.41%newTimeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 225,000 shares 225,000$1.22M0.39%newTimeline
ATYRATYR PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 600,000 shares 600,000$1.17M0.38%newTimeline
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 280,981 shares; 2023Q3: 705,881 shares; 2023Q4: 725,000 shares; 2024Q1: 675,000 shares 675,000$1.15M0.37%-50,000Timeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 35,000 shares 35,000$1M0.32%newTimeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 20,000 shares 20,000$934K0.3%newTimeline
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 375,000 shares; 2023Q2: 215,000 shares; 2023Q3: 215,000 shares; 2023Q4: 165,000 shares; 2024Q1: 165,000 shares 165,000$858K0.28%0Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 219,331 shares 219,331$713K0.23%newTimeline
NTLAINTELLIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: not reported; 2023Q4: not reported; 2024Q1: 25,000 shares 25,000$688K0.22%newTimeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
XBISPDR SERIES TRUST S&P BIOTECHput250,000$23.7M-50,000
VKTXVIKING THERAPEUTICS INC COMcall80,000$6.56Mnew
CYTKCYTOKINETICS INC COM NEWcall75,000$5.26M-5,000
IMVTIMMUNOVANT INC COMcall150,000$4.85Mnew
ACADACADIA PHARMACEUTICALS INC COMcall200,000$3.7Mnew
INTRA-CELLULAR THERAPIES INCINTRA-CELLULAR THERAPIES INC COMMON STOCKcall50,000$3.46Mnew
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INC COMcall300,000$2.69Mnew

Sold out in Q1 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
IWMISHARES TR250,000$50.2Mcall
XBISPDR SERIES TRUST250,000$22.3Mcall
MLTXMOONLAKE IMMUNOTHERAPEUTICS250,000$15.1Mcall
AMBRX BIOPHARMA INCAMBRX BIOPHARMA INC475,000$6.76Mshares
APLSAPELLIS PHARMACEUTICALS INC100,000$5.99Mcall
ARGXARGENX SE15,000$5.71Mshares
AMLXAMYLYX PHARMACEUTICALS INC200,000$2.94Mcall
ASNDASCENDIS PHARMA A/S20,000$2.52Mshares
RVMDREVOLUTION MEDICINES INC75,000$2.15Mput
CYMABAY THERAPEUTICS INCCYMABAY THERAPEUTICS INC90,000$2.13Mshares
INHIBRX INCINHIBRX INC35,000$1.33Mshares
BLUEBIRD BIO INCBLUEBIRD BIO INC465,000$642Kshares
VERONA PHARMA PLCVERONA PHARMA PLC30,000$596Kshares

How Q1 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-24-000902 base2024-05-15acceptance time not in the bulk data set